CIK 0001228627
- Non-accelerated filer
- Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 113516358
- Phone
- +1 984-884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,211,769
- in 7 filings, $50K under 10b5-1 plans
Net −$3,211,769. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Foundation Fighting Blindness Retinal Degeneration Fund −$2.8M Director sold 15% of stake
- Gagnon Robert E. −$177K Chief Financial Officer sold 7% of stake
- Magrath George −$145K Chief Executive Officer sold 2% of stake
- YERXA BENJAMIN R −$117K President sold 5% of stake
- SCHACHLE JOSEPH K −$17K Chief Operating Officer sold 2% of stake
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-28 | Suzdak Peter David Chief Executive Officer | Exercise or conversion | +6,250 | 22,250 | ||
| 2018-02-28 | Suzdak Peter David Chief Executive Officer | Exercise or conversion · Restricted Stock Units | +6,250 | 18,750 | ||
| 2018-01-26 | Suzdak Peter David Chief Executive Officer | Grant or award · Stock Option (right to buy) | +112,271 | 112,271 | ||
| 2018-01-26 | Nolan Lisa Chief Business Officer | Grant or award · Stock Option (right to buy) | +42,101 | 42,101 | ||
| 2018-01-26 | Benaim Ely Chief Medical Officer | Grant or award · Stock Option (right to buy) | +45,443 | 45,443 | ||
| 2018-01-02 | Swirsky Douglas J President and CFO | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2017-08-16 | Suzdak Peter David Chief Executive Officer | Grant or award | +10,000 | $1.99 | $20K | 16,000 |
| 2017-04-11 | CARTHY MARK Director | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2017-04-11 | Cheong Kwang Soo Director | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2017-04-11 | Rodgers Richard J Director | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2017-04-11 | Brandt Peter C. Director | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2017-04-11 | Beever Charles Director | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2017-04-10 | Ahn Chang Ho Director | Exercise or conversion | +250,000 | $0.31 | $78K | 6,260,000 |
| 2017-04-10 | Ahn Chang Ho Director | Sale | −250,000 | $0.70 | $175K | 6,010,000 |
| 2017-04-10 | Ahn Chang Ho Director | Exercise or conversion · Stock Option (right to purchase) | −250,000 | 0 | ||
| 2017-01-20 | Jeong Tae Heum Chief Financial Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2017-01-20 | Jeong Tae Heum Chief Financial Officer | Grant or award · Restricted Stock Units | +63,000 | 63,000 | ||
| 2017-01-20 | Suzdak Peter David Chief Executive Officer | Grant or award · Stock Option (right to buy) | +1,175,000 | 1,175,000 | ||
| 2017-01-20 | Suzdak Peter David Chief Executive Officer | Grant or award · Restricted Stock Units | +250,000 | 250,000 | ||
| 2017-01-20 | Benaim Ely Chief Medical Officer | Grant or award · Stock Option (right to buy) | +450,000 | 450,000 |
Page 16 of 22 · 437 trades